LaFleur & Godfrey LLC Has $27.37 Million Holdings in Stryker Co. (NYSE:SYK)

LaFleur & Godfrey LLC cut its position in shares of Stryker Co. (NYSE:SYK) by 2.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 76,029 shares of the medical technology company’s stock after selling 2,230 shares during the quarter. Stryker accounts for about 3.8% of LaFleur & Godfrey LLC’s investment portfolio, making the stock its 5th largest holding. LaFleur & Godfrey LLC’s holdings in Stryker were worth $27,374,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in SYK. Edgestream Partners L.P. acquired a new stake in shares of Stryker during the 2nd quarter worth approximately $369,000. AE Wealth Management LLC increased its position in Stryker by 101.8% in the second quarter. AE Wealth Management LLC now owns 3,414 shares of the medical technology company’s stock worth $1,162,000 after buying an additional 1,722 shares during the period. Pacer Advisors Inc. boosted its holdings in shares of Stryker by 8.4% during the second quarter. Pacer Advisors Inc. now owns 27,438 shares of the medical technology company’s stock valued at $9,336,000 after acquiring an additional 2,122 shares during the period. Sei Investments Co. grew its position in shares of Stryker by 4.0% during the second quarter. Sei Investments Co. now owns 168,336 shares of the medical technology company’s stock worth $57,271,000 after acquiring an additional 6,443 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its holdings in shares of Stryker by 69.7% in the 2nd quarter. Thrivent Financial for Lutherans now owns 87,244 shares of the medical technology company’s stock worth $29,685,000 after acquiring an additional 35,833 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on SYK. Robert W. Baird upped their target price on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a report on Thursday, January 9th. Truist Financial boosted their price target on Stryker from $380.00 to $409.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. Wells Fargo & Company raised their price target on Stryker from $405.00 to $427.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Finally, Barclays upped their price objective on shares of Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a report on Thursday, October 31st. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $405.80.

Stryker Stock Performance

Shares of NYSE SYK opened at $383.91 on Monday. The company has a market capitalization of $146.35 billion, a P/E ratio of 41.15, a price-to-earnings-growth ratio of 2.51 and a beta of 0.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. Stryker Co. has a one year low of $307.23 and a one year high of $398.20. The business’s 50-day moving average price is $375.51 and its two-hundred day moving average price is $358.98.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same period in the previous year, the firm posted $2.46 earnings per share. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. Analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. Stryker’s dividend payout ratio is currently 36.01%.

Insider Activity

In related news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 5.50% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.